GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Oncolytics Biotech Inc (NAS:ONCY) » Definitions » Accounts Receivable

ONCY (Oncolytics Biotech) Accounts Receivable : $0.00 Mil (As of Dec. 2024)


View and export this data going back to 2001. Start your Free Trial

What is Oncolytics Biotech Accounts Receivable?

Accounts Receivable are created when a customer has received a product but has not yet paid for that product. Oncolytics Biotech's accounts receivables for the quarter that ended in Dec. 2024 was $0.00 Mil.

Accounts receivable can be measured by Days Sales Outstanding.

In Ben Graham's calculation of Net-Net Working Capital, accounts receivable are only considered to be worth 75% of book value. Oncolytics Biotech's Net-Net Working Capital per share for the quarter that ended in Dec. 2024 was $0.02.


Oncolytics Biotech Accounts Receivable Historical Data

The historical data trend for Oncolytics Biotech's Accounts Receivable can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Oncolytics Biotech Accounts Receivable Chart

Oncolytics Biotech Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Accounts Receivable
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Oncolytics Biotech Quarterly Data
Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24
Accounts Receivable Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Oncolytics Biotech Accounts Receivable Calculation

Accounts Receivable is money owed to a business by customers and shown on its Balance Sheet as an asset.


Oncolytics Biotech Accounts Receivable Explanation

1. Accounts Receivable are created when a customer has received a product but has not yet paid for that product. Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's accounts receivables are being managed.

Oncolytics Biotech's Days Sales Outstanding for the quarter that ended in Dec. 2024 is calculated as:

2. In Ben Graham's calculation of Net-Net Working Capital (NNWC), Oncolytics Biotech's accounts receivable are only considered to be worth 75% of book value:

Oncolytics Biotech's Net-Net Working Capital Per Share for the quarter that ended in Dec. 2024 is calculated as:

Net-Net Working Capital Per Share
=(Cash And Cash Equivalents+0.75 * Accounts Receivable+0.5 * Total Inventories-Total Liabilities
-Preferred Stock-Minority Interest)/Shares Outstanding (EOP)
=(11.19+0.75 * 0+0.5 * 0-9.97
-0-0)/80.020
=0.02

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Be Aware

Net receivables tells us a great deal about the different competitors in the same industry. In competitive industries, some attempt to gain advantage by offering better credit terms, causing increase in sales and receivables.

If company consistently shows lower % Net receivables to gross sales than competitors, then it usually has some kind of competitive advantage which requires further digging.

Average Days Sales Outstanding is a good indicator for measuring a company's sales channel and customers. A company may book great revenue and earnings growth but never receive payment from their customers. This may force a write-off in the future and depress future earnings.


Oncolytics Biotech Accounts Receivable Related Terms

Thank you for viewing the detailed overview of Oncolytics Biotech's Accounts Receivable provided by GuruFocus.com. Please click on the following links to see related term pages.


Oncolytics Biotech Business Description

Traded in Other Exchanges
Address
322 11th Avenue S.W, Suite 804, Calgary, AB, CAN, T2R 0C5
Oncolytics Biotech Inc is a clinical-stage biopharmaceutical company. The company is focused on the discovery and development of pharmaceutical products for the treatment of cancers that have not been treated with therapeutics. It is developing pelareorep, an immunotherapeutic agent that improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The other projects in the company's pipeline include Bracelet-1 for the treatment of Breast Cancer, Goblet cohort-1, and Goblet cohort-5 for the treatment of Gastro-Intestinal Cancer among others.